

CIRCULAR NO. 9 OF 2021

5 March 2021

TO: Holders of licences or permits issued by MCAZ

FEE SCHEDULE

The Authority draws its attention to its Licence or Permit Holders of the Fee Schedule below effective 2021 -

FEES

In this schedule —

“finished product”, in relation to a medicine, means a medicine which is wholly manufactured outside Zimbabwe and is imported into Zimbabwe and ready for sale without having to be relabelled or repackaged;

“line extension of a medicine” means any additional strength or pharmaceutical forms excluding novel dosage forms or delivery systems;

“orphan medicine” means a medicine, which is used in low volumes and is intended for the treatment of conditions of low morbidity as determined from time to time by the Authority.

| Item | | | USD | |
|------|--------|--|------|--|
| 1. | | Application for the issue of a licence for— | | |
| | (a) | Premises, other than a pharmaceutical manufacturer's premises— | | |
| | (i) | pharmacy (in the Central Business District of a city) | 1000 | |
| | (ii) | pharmacy (in any other urban location) | 500 | |
| | (iii) | Pharmacy under a rural district council | 300 | |
| | (iv) | dispensing medical practitioner or veterinary surgeon | 250 | |
| | (v) | industrial clinic | 100 | |
| | (vi) | dispensary at a local authority clinic | 25 | |
| | (vii) | dispensary at public health institution | 25 | |
| | (viii) | any other clinic | 75 | |

| Item | | | USD | |
|------|-------|---|------|--|
| | (b) | a pharmaceutical manufacturer's premises— | | |
| | (i) | a sterile pharmaceutical manufacturing unit | 3000 | |
| | (ii) | a pharmaceutical manufacturer's premises with more than 3 dosage forms and not including sterile product manufacturing facilities | 2500 | |
| | (iii) | a pharmaceutical manufacturer's premises with up to 3 dosage forms | 2000 | |
| | (c) | a restricted pharmaceutical manufacturing premises | 1500 | |
| | (d) | a person other than a pharmacist or nurse | 60 | |
| | (e) | a nurse | 40 | |
| | (f) | a pharmacist | 30 | |
| | (g) | A local authority nurse | 10 | |
| 2. | | Application for the renewal of a licence for— | | |
| | (a) | a person other than a pharmacist or nurse | 40 | |
| | (b) | a nurse | 30 | |
| | (c) | a local authority nurse | 10 | |
| | (c) | a pharmacist | 20 | |
| | (d) | a premises other than a pharmaceutical manufacturer's premises | | |
| | (i) | pharmacy (in the Central Business District of a city) | 500 | |
| | (ii) | pharmacy (in any other urban location) | 250 | |
| | (iii) | Pharmacy under a rural district council | 100 | |
| | (iv) | dispensing medical practitioner/veterinary surgeon | 125 | |
| | (iv) | industrial clinic | 60 | |
| | (vi) | dispensary at a local authority clinic | 25 | |

| Item | | | USD | |
|------|-----|--|-------------------------------------|--|
| | | (vii) dispensary at a public health institution | 25 | |
| | | (viii) other clinics | 50 | |
| | (e) | a pharmaceutical manufacturer's premises- | | |
| | | (i) a sterile pharmaceutical manufacturing unit | 2000 | |
| | | (ii) a pharmaceutical manufacturer's premises with more than 3 dosage forms and not including sterile product manufacturing facilities | 1500 | |
| | | (iii) a pharmaceutical manufacturer's premises with up to 3 dosage forms | 1200 | |
| | (f) | a restricted pharmaceutical manufacturing premises | 1000 | |
| 3. | | Inspection of premises — | | |
| | (a) | Pharmaceutical manufacturer's premises | 1000 | |
| | (b) | Other premises | 200 | |
| | (c) | Other premises, expedited inspection | 400 plus costs of the re-inspection | |
| | | | | |
| 4. | | Application for the temporary renewal of a licence in terms of <u>section 60(7) of the Act</u> | 100 | |
| 5. | | Application for the issue of a permit for — | | |
| | (a) | a wholesale dealer | 1750 | |
| | (b) | a restricted wholesale dealer | 250 | |
| | (c) | a sales representative | 60 | |
| 6. | | Application for the renewal of a permit for— | | |
| | (a) | a wholesale dealer | 900 | |

| Item | | | USD | |
|------|--------|---|-------|--|
| | (b) | a restricted wholesale dealer | 150 | |
| | (c) | a sales representative | 50 | |
| 7. | | Application for a registration of a medicine— | | |
| | (a) | in the case of a medicine imported into Zimbabwe as a finished product for— | | |
| | (i) | a new chemical entity including dosage form or a delivery system (human) | 3 000 | |
| | (ii) | a new chemical entity including dosage form or a delivery system (veterinary) | 2 000 | |
| | (iii) | a generic medicine (human) | 2 500 | |
| | (iv) | a generic medicine (veterinary) | 1 500 | |
| | (v) | a line extension of a medicine (human) | 1 500 | |
| | (vi) | a line extension of a medicine (veterinary) | 1000 | |
| | (vii) | orphan medicine | 750 | |
| | (viii) | a previously registered medicine | 750 | |
| | (vii) | resubmission of an application | 600 | |
| | (b) | in the case of a medicine imported into Zimbabwe and which is re-labelled or repacked before being sold as a finished product — | | |
| | (i) | human medicine | 1000 | |
| | (ii) | Veterinary medicine | 600 | |
| | (iii) | a previously registered medicine | 500 | |
| | (iv) | resubmission of an application | 450 | |
| | (c) | in any other case — | | |
| | (i) | human medicine | 450 | |
| | (ii) | veterinary medicine | 300 | |
| | (ii) | a previously registered medicine | 375 | |

| Item | | | USD | |
|------|-----|--|-------|--|
| | | (iii) resubmission of an application | 300 | |
| | (d) | In the case of expedited review of— | | |
| | | (i) a new chemical entity | 4 500 | |
| | | (ii) a generic medicine | 4 000 | |
| | | (iii) a line of extension of a medicine | 3 000 | |
| 8. | | Retention of a registered medicine, annually— | | |
| | (a) | in the case of a medicine for human use imported into Zimbabwe as a finished product | 500 | |
| | (b) | in the case of a veterinary medicine imported into Zimbabwe as a finished product | 300 | |
| | (c) | in the case of a medicine imported into Zimbabwe and which is relabelled and repackaged before being sold as a finished product— | | |
| | | (i) human medicine | 225 | |
| | | (ii) veterinary medicine | 150 | |
| | (d) | In any other case— | | |
| | | (i) human medicine | 100 | |
| | | (ii) veterinary medicine | 75 | |
| 9. | | Application to export or import an unregistered medicine in terms of <u>section 75 of the Act</u> — | | |
| | (a) | individual prescription | 10 | |
| | (b) | institutions- per medicine — | | |
| | | (i) Hospitals | 15 | |
| | | (ii) non-government organisations (NGO's) | 10 | |
| | | (iii) other (wholesale dealers, etc) | 50 | |
| | (c) | clinical trials - per medicine — | | |

| Item | | | USD | |
|------|--------|---|-----|--|
| | (i) | foreign sponsored | 20 | |
| | (ii) | locally sponsored | 10 | |
| | (d) | Authorisation to import an unregistered veterinary product where - | | |
| | (i) | no registered alternative is available and no application for registration has been submitted | 150 | |
| | (ii) | no application for registration has been submitted | 250 | |
| 10. | | Any amendment to the original application for the registration of medicine — | | |
| | (a) | in the case of a medicine imported into Zimbabwe as a finished product — | | |
| | (i) | indications | 400 | |
| | (ii) | category for distribution | 400 | |
| | (iii) | formulation | 300 | |
| | (iv) | stability data | 300 | |
| | (v) | change of additional manufacturer | 300 | |
| | (vi) | Batch data | 300 | |
| | (vii) | bioavailability/bioequivalence | 300 | |
| | (viii) | Promotional material | 100 | |
| | (ix) | any other matter | 250 | |
| | (b) | in the case of a medicine imported into Zimbabwe and which is re-labelled or repacked before being sold as a human or veterinary medicine | | |
| | (i) | Indications | 225 | |
| | (ii) | category for distribution | 225 | |
| | (iii) | Formulation | 150 | |
| | (vi) | stability data | 150 | |
| | (v) | change of or additional manufacturer | 150 | |

| Item | | | USD | |
|------|-----|--|-------|--|
| | | (vi) batch data | 150 | |
| | | (vii) bioavailability/bioequivalence | 150 | |
| | | (viii) Promotional material | 100 | |
| | | (ix) any other | 130 | |
| | (c) | any other case— | | |
| | | (i) Indications | 100 | |
| | | (ii) category for distribution | 100 | |
| | | (iii) Formulation | 75 | |
| | | (iv) stability data | 75 | |
| | | (v) change of or additional manufacturer | 75 | |
| | | (vi) batch data | 75 | |
| | | (vii) bioavailability/bioequivalence | 75 | |
| | | (viii) Promotional material | 50 | |
| | | (ix) any other | 65 | |
| 11. | | Application to conduct a clinical trial of a medicine— | | |
| | (a) | Funded by a local sponsor— | | |
| | | (i) human medicine | 1000 | |
| | | (ii) Veterinary medicine | 500 | |
| | | (ii) sub-study | 500 | |
| | | (iii) operational research study | 500 | |
| | | (iv) observational study | 100 | |
| | | (v) any other case | 50 | |
| | (b) | funded by a foreign sponsor— | | |
| | | (i) human medicine phase I study | 5 000 | |
| | | (ii) human medicine phase II study | 4 000 | |

| Item | | | USD | |
|------|--------|--|---|--|
| | (iii) | human medicine phase III study or phase IV study | 3 000 | |
| | (iv) | Veterinary medicine | 1 000 | |
| | (v) | Sub-study | 1000 | |
| | (vi) | in any other case | 500 | |
| | (vii) | Operational | 1 000 | |
| | (viii) | bioequivalence/bioavailability | 500 | |
| | (ix) | Observational | 200 | |
| | (x) | in any other case | 200 | |
| | (c) | Any amendment to original application funded by a local sponsor— | | |
| | (i) | Initial | 25 | |
| | (ii) | Subsequent | 25 | |
| | (d) | any amendment to original application funded by a foreign sponsor— | | |
| | (i) | Initial | 100 | |
| | (ii) | Subsequent | 100 | |
| | (e) | In the case of an expedited consideration of any process listed in paragraphs (a) to (d) | Fees listed in (a) to (d) for that particular process plus 50% of the fee | |
| 12. | | Application to import psychotropic substances | 25 | |
| 13. | | Application to export psychotropic substances | 25 | |
| 14. | | Application for authorisation to procure, possess, administer or distribute medicine | 25 | |
| 15 | | Application for a permit to supply veterinary medicines (VMGD) | 100 | |
| 16. | | Application for any duplicate copy of a current licence or permit | 15 | |

| Item | | | USD | |
|------|-----|---|-----|---|
| 17. | | Application for a duplicate copy of a certificate of registration of a medicine— | | |
| | (a) | in the case of a medicine imported into Zimbabwe as a finished product | 100 | - |
| | (b) | in the case of a medicine imported into Zimbabwe and which is re-labelled or repacked before being sold as a human or veterinary medicine | 40 | |
| | (c) | in any other case | 25 | |
| 18. | | Application for a copy of a certificate of registration— | | |
| | (a) | in the case of a medicine imported into Zimbabwe as a finished product | 50 | |
| | (b) | in the case of a medicine imported into Zimbabwe and which is re-labelled or repacked before being sold as a human or veterinary medicine | 25 | |
| | (c) | in any other case | 10 | |
| 19. | | Application to manufacture a medicine on contract for export or otherwise— | | |
| | (a) | in the case of a foreign principal | 250 | |
| | (b) | in the case of a local principal | 50 | |
| 20. | | Approval of advertisements — | | |
| | (a) | in the case of an initial submission | 30 | |
| | (b) | in the case of a resubmission of an advertisement | 20 | |
| 21. | | Any amendment to the original application and additional information for— | | |
| | (a) | licence or permit | 15 | |
| | (b) | authorisation to import an unregistered medicine | 15 | |

| Item | | | USD | |
|------|-----|--|-----|--|
| 22. | | Application for the issue of a certificate of free sale (COF's) | 40 | |
| 23. | | Application for the issue of a certificate of a pharmaceutical product (CPP) | 40 | |
| 24. | | Fee for conducting hearings | 500 | |
| 25. | | Application for issue of a WHO-type GMP certificate | 40 | |
| 26 | | Application for the approval of a complementary medicine | | |
| | (a) | in the case of a complementary medicine imported into Zimbabwe as a finished product | 600 | |
| | (b) | in the case of a complementary medicine imported into Zimbabwe and which is relabelled or repackaged before being sold | 300 | |
| | (c) | in any other case (locally manufactured) | 200 | |
| 27 | | Retention to sell an approved complementary medicine, annually | | |
| | (a) | in the case of a complementary medicine imported into Zimbabwe as a finished product | 150 | |
| | (b) | in the case of a complementary medicine imported into Zimbabwe and which is relabelled or repackaged before being sold | 90 | |
| | (c) | in any other case (locally manufactured) | 50 | |
| 28 | | Any amendment to the original application for the approval of a complementary medicine | | |
| | (a) | in the case of a complementary medicine imported into Zimbabwe as a finished product | 100 | |
| | (b) | in the case of a complementary medicine imported into Zimbabwe and which is relabelled or repackaged before being sold | 75 | |

| Item | | | USD | |
|------|--|--|---|--|
| | | | | |
| | | (c) in any other case (locally manufactured) | 50 | |
| 29 | | Application for a replacement or copy of a certificate of approval | | |
| | | (a) in the case of a complementary medicine imported into Zimbabwe as a finished product | 50 | |
| | | (b) in the case of a complementary medicine imported into Zimbabwe and which is relabelled or repackaged before being sold | 30 | |
| | | (c) in any other case (locally manufactured) | 20 | |
| 30 | | Application for a permit to import medicines | 25 | |
| 31 | | Application for a permit to export medicines | 20 | |
| 32 | | Consignment verification fee for importation of medicines | 1 percent of Cost Insurance and Freight (CIF) value | |
| 33 | | Application for a permit to import a precursor or certain chemical substance | 25 | |
| 34 | | Application for a permit to export a precursor or certain chemical substance | 25 | |
| 35 | | Consignment verification fee for importation of a precursor or certain chemical substance | 0.5 percent of Cost Insurance and Freight (CIF) value | |
| 36 | | Application for extension of a permit to import or export a precursor or certain chemical substance | 25 | |
| 37 | | Application for a licence to acquire, possess and administer Part IV drugs | 25 | |

| Item | | | USD | |
|------|--|---|-----|--|
| 38 | | Application for renewal of a licence to acquire, possess and administer Part IV drugs | 25 | |
| 39 | | Application for a licence to import Part IV drugs | 40 | |
| 40 | | Application for a licence to export Part IV drugs | 40 | |

Notes

1. The fees specified herein shall not apply to any person or institution exempted by the Authority.
2. Laboratory fees levied in terms of section 73A of the Act shall be charged by the Authority on a cost recovery basis
3. GMP inspection costs shall be charged by the Authority on a cost recovery basis
4. Inspection fees for new premises are part of the application fee.
5. Restricted pharmaceutical manufacturing premises where only repackaging and labelling is done.
6. Second and subsequent inspections carried out due to unsuccessful initial inspections will attract an inspection fee and costs of the inspection as stipulated in item 3 (c).
7. A restricted wholesale dealer is a wholesale dealer who is not in the business of wholesaling but applies for a special permit to supply products by wholesale (e.g. not for profit) in terms of items 5(b) and 6(b).
8. The expedited fee in item 7 is for registration of medicines reviewed expeditiously.
9. Incomplete applications will attract an amendment fee as stipulated in items 10 and 21.
10. The application fee item 25 applies to an application submitted within 6 months of the last inspection. Beyond 6 months the premises concerned have to pass a re-inspection prior to the issuance of a WHO-type cGMP certificate.”.

Yours faithfully

MEDICINES CONTROL AUTHORITY OF ZIMBABWE



R.T. RUKWATA (Mr)

ACTING DIRECTOR-GENERAL